Jade Biosciences, Inc.
JBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$548.77M
Close$
$2.80
87.3% downside
Current Fair Value
87.3% downsideOvervalued by 87.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $548.77 Million |
|---|---|
| Enterprise Value | $494.36 Million |
| Dividend Yield | $2.40 (-) |
| Earnings per Share | $-4.06 |
| Beta | 1.45 |
| Outstanding Shares | 57,777,165 |
Return
| Return on Equity | -55.74% |
|---|---|
| Return on Assets | -51.74% |
| Return on Invested Capital | -52.44% |
Valuation & Multiples
| P/E Ratio | -7.5 |
|---|---|
| PEG | -0.5 |
| Price to Sales | - |
| Price to Book Ratio | 4.39 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.17 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 6.2441▲ 624.41% |
|---|---|
| Total Calls | 11,200▲ Infinity% |
| Total Puts | 69,934▼ 26.73% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 158.95%▲ 40.03% |
|---|---|
| Total Invested | $700.29M▼ 3.58% |
| Investors Holding | 123▲ 17.00% |
ESG Score
No data
About Jade Biosciences, Inc.
50 employees
CEO: Tom Frohlich Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) ...